Labcorp (NYSE:LH) Shares Unloaded Rep. April McClain Delaney

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of Labcorp Holdings Inc. (NYSE:LH). In a filing disclosed on September 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in Labcorp stock on August 6th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of Wabtec (NYSE:WAB) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Viking (NYSE:VIK) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Trimble (NASDAQ:TRMB) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Transdigm Group (NYSE:TDG) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Tractor Supply (NASDAQ:TSCO) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Middleby (NASDAQ:MIDD) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Teledyne Technologies (NYSE:TDY) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of STERIS (NYSE:STE) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Somnigroup International (NYSE:SGI) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Signet Jewelers (NYSE:SIG) on 8/25/2026.

Labcorp Stock Performance

Shares of NYSE:LH traded up $4.40 on Friday, reaching $311.36. 809,927 shares of the company’s stock were exchanged, compared to its average volume of 635,612. The company has a fifty day moving average of $310.39 and a 200-day moving average of $281.94. Labcorp Holdings Inc. has a twelve month low of $244.52 and a twelve month high of $341.80. The company has a market capitalization of $25.25 billion, a price-to-earnings ratio of 25.75, a PEG ratio of 1.74 and a beta of 0.88. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69.

Labcorp (NYSE:LH) last released its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, beating analysts’ consensus estimates of $4.78 by $0.21. The company had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.71 billion. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business earned $4.35 earnings per share. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, research analysts predict that Labcorp Holdings Inc. will post 18.32 EPS for the current fiscal year.

Labcorp Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 28th were issued a $0.72 dividend. The ex-dividend date of this dividend was Friday, August 28th. This represents a $2.88 dividend on an annualized basis and a yield of 0.9%. Labcorp’s payout ratio is currently 23.82%.

Insiders Place Their Bets

In other Labcorp news, EVP Bryan T. Vaughn sold 234 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $66,968.46. Following the completion of the transaction, the executive vice president directly owned 6,746 shares in the company, valued at approximately $1,930,637.74. This represents a 3.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Amy B. Summy sold 924 shares of the firm’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $306.74, for a total value of $283,427.76. Following the transaction, the executive vice president directly owned 6,956 shares of the company’s stock, valued at approximately $2,133,683.44. This represents a 11.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 8,919 shares of company stock worth $2,826,593 over the last quarter. 0.84% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

LH has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $306.00 price objective on shares of Labcorp in a research note on Friday, July 31st. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Weiss Ratings raised shares of Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. Robert W. Baird set a $352.00 target price on shares of Labcorp in a report on Friday, July 31st. Finally, UBS Group boosted their target price on shares of Labcorp from $361.00 to $380.00 and gave the company a “buy” rating in a research report on Friday. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $336.36.

More Labcorp News

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp reaffirmed its 2026 guidance of adjusted EPS of $18.10 to $18.55, broadly consistent with the analyst consensus of $18.32. Maintaining guidance supports confidence in near-term earnings visibility. Labcorp Holdings Reiterates 2026 Outlook, Issues Long-Term Guidance
• Positive Sentiment: The company issued a 2029 outlook calling for compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%. The targets imply sustained expansion beyond the current year and could support a higher long-term earnings outlook. Labcorp 2026 Investor Day Announcement
• Positive Sentiment: Labcorp plans to use artificial intelligence, specialty testing, scientific capabilities and global scale to drive growth. Management also emphasized strong cash-flow generation and disciplined capital deployment, which may improve shareholder returns if execution meets expectations. Labcorp Bets Big on AI and Specialty Testing
• Neutral Sentiment: The Investor Day transcript provided additional detail on Labcorp’s strategic priorities and long-term financial framework, but the benefits depend on successful implementation and investment in new technologies and testing capabilities. Labcorp Analyst and Investor Day Transcript
• Negative Sentiment: LH recently declined about 4.3% and underperformed peers, indicating that investors may have viewed the Investor Day information as insufficient to justify the stock’s elevated valuation or may have taken profits despite the favorable long-term targets. Labcorp Stock Heads Into the Open After a 4.3 Percent Slide

Institutional Investors Weigh In On Labcorp

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. REAP Financial Group LLC boosted its holdings in shares of Labcorp by 20.4% during the 4th quarter. REAP Financial Group LLC now owns 218 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 37 shares in the last quarter. V Square Quantitative Management LLC raised its position in Labcorp by 1.7% in the first quarter. V Square Quantitative Management LLC now owns 2,418 shares of the medical research company’s stock valued at $645,000 after purchasing an additional 40 shares during the last quarter. Hilltop Holdings Inc. boosted its stake in shares of Labcorp by 2.6% during the fourth quarter. Hilltop Holdings Inc. now owns 1,631 shares of the medical research company’s stock valued at $409,000 after purchasing an additional 41 shares in the last quarter. Pinnacle Associates Ltd. grew its holdings in shares of Labcorp by 3.9% during the fourth quarter. Pinnacle Associates Ltd. now owns 1,126 shares of the medical research company’s stock worth $282,000 after purchasing an additional 42 shares during the last quarter. Finally, Larson Financial Group LLC grew its holdings in shares of Labcorp by 37.5% during the third quarter. Larson Financial Group LLC now owns 154 shares of the medical research company’s stock worth $44,000 after purchasing an additional 42 shares during the last quarter. 95.94% of the stock is owned by institutional investors.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Labcorp Company Profile

Labcorp (NYSE: LH), formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services.